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ABSTRACT: The development of new antitubercular agents for the treatment of
infections caused by multidrug-resistant (MDR) Mycobacterium tuberculosis is an urgent
priority. Pyrrolobenzodiazepines (PBDs) are a promising class of antibacterial agents
that were initially discovered and isolated from a range of Streptomyces species. Recently,
C8-linked PBD monomers have been shown to work by inhibiting DNA gyrase and
have demonstrated activity against M. tuberculosis. However, both PBD monomers and
dimers are toxic to eukaryotic cells, limiting their development as antibacterial agents.
To eliminate the toxicity associated with PBDs and explore the effect of C8-modification
with a known antibacterial agent with the same mechanism of action (i.e., ciprofloxacin,
a gyrase inhibitor), we synthesized a C8-linked PBD−ciprofloxacin (PBD−CIP, 3)
hybrid. The hybrid compound displayed minimum inhibitory concentration values of
0.4 or 2.1 μg/mL against drug-sensitive and drug-resistant M. tuberculosis strains,
respectively. A molecular modeling study showed good interaction of compound 3 with
wild-typeM. tuberculosis DNA gyrase, suggesting gyrase inhibition as a possible mechanism of action. Compound 3 is a nontoxic
combination hybrid that can be utilized as a new scaffold and further optimized to develop new antitubercular agents.
■ INTRODUCTION
Tuberculosis (TB) is one of the most serious bacterial
infections, with around 10 million new cases and an average
of almost 1.3 million deaths in 2017 alone.1 Novel strategies
are required to treat TB and specifically target drug-resistant
strains of Mycobacterium tuberculosis, which are increasing
worldwide. A lengthy multidrug regimen is needed to eradicate
the infection, which complicates the treatment of TB and
threatens our attempts to control this pandemic. Therefore,
there is an urgent need for new, improved antibiotics that will
shorten treatment times.2 Only a few new TB drugs are in
clinical trials, and since the 1960s, there have only been two
new antibiotics, bedaquiline and delaminid, developed for
treatment; these drugs are only given to patients with
extensively drug-resistant (XDR)-TB or pre-XDR-TB. The
WHO End-TB strategy aims to reduce TB deaths by 95% and
to cut new cases by 90% between 2015 and 2035 with the
ultimate aim to end the global TB epidemic.3 This goal will
only be achieved through improved TB control measures and
innovative tools for the discovery of new interventions. M.
tuberculosis has evolved many mechanisms for avoiding the
effects of antibiotics. Its waxy, impermeable coat does not
allow for the easy penetration of antibiotics, and, in addition,
the organism possesses efflux systems that allow for the rapid
expulsion of antibiotics.4 One approach for TB drug
development is the potentiation of existing antibiotics, and
this could accelerate drug discovery efforts.
Recently, the PBD class of sequence-specific DNA minor
groove binding agents has been recognized as potential
chemotherapeutic and antibacterial agents.5−8 They have a
kinetic preference for 5′-Py−G−Py-3′ sequences,9 while 5′-
AGA-3′ has been established as the thermodynamically
preferred sequence.10 PBDs are able to act as covalent binding
agents by positioning themselves securely within the DNA
minor groove and selecting for GC-rich sequences. This is
made possible by the particular three-dimensional (3D) shape
afforded to them by a chiral center at their C11a(S)-position.
PBDs can also form an aminal linkage between their C11-
position and the C2-NH2 group of a guanine base once
securely within the minor groove, due to the presence of a
“soft” electrophilic imine moiety at their N10−C11-posi-
tion.11,12 Naturally occurring PBD monomers such as
anthramycin, tomaymycin, neothramycin, and sibiromycin
form adducts that span three base pairs, with guanine in the
central position,13,14 while the larger synthetic C8-linked PBD
monomers and PBD dimers can span up to eight base
pairs.15−18 The side chains of PBD monomers play a key role
in DNA sequence recognition and fit of the PBDs within the
DNA minor groove, which has been linked to their
cytotoxicity.7 C8-substituents with pyrrole and imidazole
heterocycles,15 biaryls (e.g., 4-(1-methyl-1H-pyrrol-3-yl)-ben-
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zenamine (MPB)),16 and benzofused rings (e.g., benzofuran
and benzothiophene)17,18 have been shown to facilitate
binding and stabilization of DNA, while large bulky groups
like porphyrins reduce the ability of PBDs to bind to duplex
DNA due to steric factors.19 C8-linked PBD monomers have
shown notable antibacterial activity against MDR Gram-
positive bacteria6,8 and M. tuberculosis.20 More recently, DNA
gyrase inhibition has been reported as an additional
mechanism of action of antibacterial PBDs.6 A study by
Brucoli et al. evaluated 12 C8-linked PBD-heterocyclic
polyamide conjugates for antitubercular activity and DNA
sequence selectivity.20 These PBD conjugates exhibited
significant growth inhibition of M. tuberculosis H37Rv, with
minimum inhibitory concentrations (MICs) ranging from 0.08
to 5.19 μg/mL. As is the case for other PBD compounds, these
compounds demonstrated cytotoxicity toward mammalian
cells due to DNA binding. To eliminate the cytotoxicity
associated with PBDs,16,18 we aimed to develop an
antitubercular C8-PBD conjugate that could not be accom-
modated easily within the DNA minor groove, due to the
presence of a large C8-substituent while retaining antimyco-
bacterial activity.
We selected ciprofloxacin, a known gyrase inhibitor, as the
C8-substituent to develop a PBD−ciprofloxacin hybrid
molecule as ciprofloxacin possesses the same mechanism of
action as PBDs.6 Ciprofloxacin and other fluoroquinolones are
used in the management of MDR-TB (Figure 1), but the
emergence of fluoroquinolone-resistant M. tuberculosis is a
cause for significant concern. Alternative approaches such as
the development of hybrid molecules can overcome resistance,
extend the life span of current treatments, and expand the pool
of first-line drugs that are available for TB treatment.
Ciprofloxacin hybrids with both small molecules21 and
macromolecules22,23 have been used as a strategy to improve
activity and overcome resistance in both Gram-positive and
Gram-negative bacteria. We conjugated a C8-linker-containing
PBD to ciprofloxacin through its piperazine moiety. This
conjugation allowed the carboxylic acid group of ciprofloxacin
to remain unmodified, which is crucial for its activity and
provided a C8-PBD hybrid with a large bulky substituent,
which would influence the DNA binding and hence the toxicity
of the PBDs. The hybrid demonstrated no DNA binding and
was found to be nontoxic against eukaryotic cell lines. It was
anticipated that the synthesized PBD−CIP hybrid would
maintain its ability to interact with DNA gyrase due to its
structural similarity with C8-PBD monomers, and an in silico
study demonstrated good interaction with M. tuberculosis DNA
gyrase. The hybrid compound displayed MIC values of 0.4 or
2.1 μg/mL against drug-sensitive and drug-resistant M.
tuberculosis strains, respectively, which is comparable to the
MIC values reported for C8-linked PBDs against M. tuber-
culosis.20 This is the first report of a nontoxic C8-linked PBD
hybrid with activity against M. tuberculosis and is a starting
point for the development of nontoxic PBD molecules that do
not bind DNA as new antibiotics for TB treatment.
■ RESULTS AND DISCUSSION
Design, In Silico Modeling, and Synthesis of
Fluoroquinolone−Pyrrolobenzodiazepine Hybrid. The
fluoroquinolone−pyrrolobenzodiazepine hybrid (compound 3,
Figure 2) was designed by considering the structure−activity
relationship data available for fluoroquinolone and pyrrolo-
benzodiazepine classes of molecules. The substituted 4-
quinolone ring and the tricyclic pyrrolobenzodiazepine system
were connected through a C4 chemical spacer. The C8-
position of the PBD A-ring and C7-position of ciprofloxacin
were selected for chemical modification as the SAR data for
these chemical classes indicated that structural changes are
allowed in these positions. The OH group of the C8-position
of the PBD was linked to the C7-piperazine group of
ciprofloxacin via a 4C linker with a terminal carboxylic acid
group.
To explore the ability of compound 3 to interact with DNA
gyrase enzyme, it was docked with both wild-type and S95T
mutant gyrase (present within M. tuberculosis strains of East
Asian, Central Asian, and EuroAmerican lineages) from M.
tuberculosis. Compound 3 showed a −35.84 kcal/mol free
energy of binding and a ChemScore of 30.67 compared to a
−27.45 kcal/mol free energy of binding and a ChemScore of
24.89 observed for ciprofloxacin. The free energy of binding
and ChemScore for compound 3 against the S95T mutant
were comparable to those observed for ciprofloxacin (−28.1 vs
−27.5 kcal/mol and 24.45 vs 25.46, respectively). Compound
3 showed greater interaction with both wild-type and S95T
mutant gyrase enzyme gyrA (Figures 3 and S1, Tables S1−S4)
compared to ciprofloxacin. The ciprofloxacin component of
Figure 1. Structure of selected fluoroquinolones and pyrrolobenzodiazepine with reported activity against M. tuberculosis.
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the compound showed hydrogen bond interactions with
arginine 39 and alanine 986 residues, while the PBD
component showed hydrophobic interactions with proline
124 and tyrosine 93 residues. The interaction of compound 3
with GyrA S95T was comparable to that observed for
ciprofloxacin (Figure S2). This modeling data suggested that
compound 3 could interact with GyrA, occupying a binding
pocket close to the ciprofloxacin binding pocket. Therefore, it
was decided to synthesize the hybrid compound and evaluate
its activity against M. tuberculosis strains.
Compound 3 was synthesized according to the synthetic
scheme reported in Scheme 1. The N10 alloc−tetrahydropyr-
anyl (THP) protected pyrrolobenzodiazepine core 1 was
synthesized according to the nine-step literature-reported
procedure16. Commercially available ciprofloxacin ethyl ester
1 was coupled to the protected pyrrolobenzodiazepine core
structure 2 to form the amide bond connection required to link
t h e t w o p h a r m a c o p h o r e s . N - E t h y l -N ′ - ( 3 -
dimethylaminopropyl)carbodiimide (EDCI) and 4-dimethyla-
minopyridine (DMAP) were selected as the coupling system
for the formation of the amide bond. This was followed by
hydrolysis of the ciprofloxacin ethyl ester to generate the active
carboxylic acid. Finally, the N10 alloc−THP group was
deprotected in the presence of palladium to generate the
reactive imine group between N10 and C11 of the
pyrrolobenzodiazepine structure. The final compound (3,
PBD−CIP) was purified using liquid column chromatography
with a dichloromethane (DCM)/methanol gradient. The
compound was fully characterized by NMR and MS
spectrometric techniques prior to biological evaluation.
Evaluation of DNA Binding Ability of Compound 3.
PBDs are known to interact covalently with the DNA minor
groove, which is the key source of their eukaryotic toxicity. The
ability of compound 3 to bind and stabilize DNA was
evaluated using a Förster resonance energy transfer (FRET)-
based DNA melting assay24 using two fluorophore-labeled
oligonucleotide sequences (sequence F1: 5′-FAM-TAT-ATA-
TAG-ATA-TTT-TTT-TAT-CTA-TAT-ATA-3′-TAMRA and
sequence F2: 5′-FAM-TAT-AGA-TAT-AGA-TAT-TTT-
ATA-TCT-ATA-TCT-ATA-3′-TAMRA) to understand the
effect of the relatively bulky ciprofloxacin building block.
Netropsin, a known DNA minor groove binder, and a
previously reported C8-linked PBD with antibacterial activity,
PBD-Py-Py (GWL-78, Figure 1), were used as positive
controls. Netropsin showed a 16 °C stabilization of sequence
F1 and a 13.5 °C stabilization of sequence F2 at 1 μM; GWL-
78 showed an 18 °C stabilization of sequence F1 and a 16.5 °C
stabilization of sequence F2. However, compound 3 showed
weak stabilization of both DNA sequences, with ΔTm values
between 1 and 1.5 °C at a 1 μM concentration (drug/DNA
ratio 5:1) (Table 1). The result suggests that the bulky
ciprofloxacin substitution at the C8-position of the PBD
reduces the ability of compound 3 to interact and stabilize the
DNA sequences. Most PBD monomers stabilize duplex DNA
sequences in the range of 8−18 °C and show low micromolar
to nanomolar IC50s against eukaryotic cell lines.
5 As DNA
binding and stabilization are linked to the eukaryotic toxicity of
pyrrolobenzodiazepines,25 this lack of DNA binding observed
for compound 3 was expected to reduce the toxicity of the
newly synthesized hybrid.
Evaluation of Eukaryotic Toxicity. The aim of the study
is to develop a compound with antitubercular activity, as well
as selective toxicity toward prokaryotes. However, DNA
stabilization has been associated with cytotoxicity for PBD-
type covalent minor groove binders.25 Therefore, the
eukaryotic cytotoxicity of the synthesized compounds was
tested in the cervical cancer cell line HeLa and the nontumor
lung fibroblast WI-38 using an MTT assay with GWL-78 as
the control.26 Compound 3 did not show any notable toxicity
(>90% survival at 24 h) at the highest concentration (20 μM)
tested, while 24% HeLa cells and 41% WI-38 cells survived
after 24 h incubation with 20 μM GWL-78. These results are
encouraging, especially as standard C8-linked PBD monomers
tend to show high levels of cytotoxicity.
Microbiological Evaluation of Compound 3. The
activity of compound 3 and ciprofloxacin was determined
using M. tuberculosis H37Rv and two clinical M. tuberculosis
isolates of Beijing/W lineage, 1192/015 and 08/00483E
(multidrug-resistant, Table S5). Both clinical isolates harbor
mutations within the DNA gyrase gene (gyrA) (Table 2);
however, these mutations do not confer resistance to
fluoroquinolones including ciprofloxacin.
A modified resazurin microtiter assay in combination with a
modified Gompertz function27 was used to generate MIC
values for compound 3 and ciprofloxacin. A dose-dependent
response of bacterial growth inhibition was observed for all
strains exposed to compound 3 or ciprofloxacin, thereby
confirming antimicrobial activity for both compounds (Figures
4 and 5).
MIC values were calculated for three M. tuberculosis strains
(H37Rv, Beijing susceptible strain 1192/015, and Beijing drug-
resistant strain 08/00483E) that were exposed to either
ciprofloxacin or compound 3 at concentration ranges of
0.094−6.036 and 0.048−3.1 μM, respectively. Three in-
dependent replicate experiments were performed for each
strain and each antibiotic. An MIC was determined for each
replicate experiment using a modified Gompertz function. The
Figure 2. Design of the fluoroquinolone−pyrrolobenzodiazepine
hybrid.
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three independent MIC values for each strain were used to
calculate the mean MIC and standard deviation from the
mean.
The MICs of ciprofloxacin for both clinical isolates were not
significantly different from the MIC calculated for M.
tuberculosis H37Rv (Figure 4A and Table 3). In contrast, the
exposure of M. tuberculosis strains to compound 3 resulted in
markedly different dose-dependent responses, and the MIC
values recorded for M. tuberculosis Beijing/W strains were
significantly greater than the MIC recorded for M. tuberculosis
H37Rv.
The MIC value for compound 3 against H37Rv (0.413 ±
0.0004 μg/mL) is comparable to that reported for C8-linked
PBD monomers with traditional heteroaromatic building
blocks (MIC range 5.19−0.08 μg/mL) by Brucoli et al.20
However, C8-PBD monomers with heteroaromatic building
blocks are cytotoxic15 and not considered desirable candidates
for development as antimicrobial agents. Therefore, the activity
observed for the noncytotoxic compound 3 is encouraging and
provides an opportunity to further improve the activity of this
chemical series through medicinal chemistry optimization.
Compound 3 had comparable activity to ciprofloxacin in
inhibiting the growth of M. tuberculosis H37Rv, suggesting that
the increased molecular level interaction of compound 3 with
DNA gyrase, as indicated by molecular modeling data, did not
result in a more active compound against M. tuberculosis
compared to ciprofloxacin.
Although inhibitory to the growth of clinical M. tuberculosis
strains (1192/015 and 08/00483E) at low micromolar
concentrations, compound 3 is approximately fivefold less
active than ciprofloxacin against these strains. The molecular
modeling study suggested greater interaction with S95T
mutant gyrase A, which is present in these strains, compared
to that of ciprofloxacin. Therefore, this reduction in activity
observed for compound 3 was surprising. In the absence of a
biochemical assay to directly measure the inhibition of the
Figure 3. Two-dimensional (2D) and 3D structures of ciprofloxacin (A, B) and compound 3 (C, D) within the binding site of the wild type of
DNA gyrase A.
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mutant S95T enzyme, it is not possible to fully ascertain the
reason behind the reduction in activity. The relatively higher
molecular weight of compound 3 might play a role in its ability
to cross the mycobacterial membrane, particularly if cell wall
alteration contributes to the resistance of these clinical strains
against antitubercular agents. These results suggest that the
addition of pyrrolobenzodiazepine to ciprofloxacin has reduced
its activity against mutant strains through an unknown
mechanism. Potential explanations for this observation include
greater affinity of efflux pumps for compound 3 or reduced
permeability of compound 3 through the mycobacterial cell
wall. This is supported by the observation that Beijing/W M.
tuberculosis strains (includingM. tuberculosis 1192/015 and 08/
00483E) harbor a deletion of the RD105 region of the genome
(Rv0071−Rv0074) that results in the thickening of the cell
wall and reduced intracellular concentrations of antibiotics.28
The deletion of the RD105 region results in a gene fusion of
Rv0071 and Rv0074 generating a gene product with
carbopeptidase activity that can cleave peptidoglycan, poten-
tially enhancing the cross-linking of peptidoglycan to increase
the thickness of the cell wall. Further experimentation would
be required to elucidate these hypotheses. Calculation of
Scheme 1. Synthetic Scheme for PBD−CIP (3)
Table 1. DNA Duplex Stabilization for Compound 3 and
Control Compoundsa
ΔTm at 1 μM
compounds sequence F1 sequence F2
3 1.1 ± 0.2 1.5 ± 0.5
GWL-78 18.0 ± 0.2 16.5 ± 0.5
netropsin 16.0 ± 0.3 13.5 ± 0.2
ciprofloxacin 0.4 ± 0.2 0.2 ± 0.3
aΔTm values are reported in the table at °C in comparison to the
oligo only. Assay conducted in triplicate.
Table 2. Mutations Present in M. tuberculosis Strains 1192/
015 and 08/00483E gyrA But Absent in M. tuberculosis
H37Rv
position mutation annotation gene description
7362 G → C E21Q (GAG → CAG) gyrA DNA gyrase A
7585 G → C S95T (AGC → ACC) gyrA DNA gyrase A
9304 G → A G668D (GGC → GAC) gyrA DNA gyrase A
Figure 4. Effect of compound 3 and GWL-78 against HeLa and WI-38 cell line. The lack of cytotoxicity observed for compound 3 was statistically
significant compared to that for GWL-78.
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c log P by ChemBioOffice 16.0 showed that compound 3 was
more hydrophobic (c log P 1.85) compared to ciprofloxacin
(c log P −0.72). This increased hydrophobicity may reduce
uptake and therefore the intracellular concentration of
compound 3 in the Beijing/W strains due to the hydrophilic
nature of peptidoglycan. This can also affect the efflux potential
of the compound as molecules with more hydrophobic side
chains are considered as preferred substrates of efflux pumps.29
The mutations noted in Table 2 may further reduce the
ability of compound 3 to bind effectively with the mutated
DNA gyrase A, although the molecular modeling study
suggested comparable binding affinities for both wild-type
and S95T mutant enzymes. Despite compound 3 being less
active than ciprofloxacin in some strains, the identification of a
new hybrid chemical class with activity against M. tuberculosis
provides the drug development pipeline with new chemical
scaffolds to work on. Both the pharmacophores, pyrrolobenzo-
diazepine and fluoroquinolones, which are present in the
hybrid compound 3 have shown clinical utility in cancer and
infection, respectively.
Compound 3 displayed a dose-dependent inhibition of
growth of both the clinical and laboratory, M. tuberculosis
strains, at concentrations in the low micromolar range.
Although the activity of compound 3 was reduced in the
clinical strains compared to that of H37Rv, this was not
unexpected as reduced activity has been observed previously in
these clinical strains (unpublished data). It is very promising
that inhibition was observed in these clinical strains. An
increase in the MIC observed in the Beijing strains was likely
to be due to phenotypic resistance mechanisms, such as
reduced permeability, which will be investigated further. These
findings highlight the need for the evaluation of novel
compounds against different lineages and clinically adapted
strains. Novel drugs are needed for TB treatment, and
compound 3 is a starting point for further development,
particularly as the toxic effects of DNA binding have been
removed. This noncytotoxic and novel chemical scaffold can be
used to develop new antitubercular agents or as a chemical
biology tool to study antimicrobial resistance in M. tuberculosis.
■ EXPERIMENTAL SECTION
Chemistry. Solvents and reagents have been obtained from
several commercial sources, including Sigma-Aldrich, Fluo-
rochem, Alfa Aesar, and Fisher Scientific. Thin-layer
chromatography analyses were performed on plates coated
with silica gel (Merck, F254 plates, silica gel 60). The final
plates were visualized under ultraviolet radiation (UV) at
either 254 or 365 nm. Manual flash chromatography utilized in
the purification of the crude of the reaction was performed
using silica gel as a stationary phase (silica gel from Merck,
230−400 mesh). The solvents were routinely evaporated
under vacuum using an RC-600 evaporating system (from
KNF), equipped with an SC-920 G vacuum pump (KNF). The
final compounds, when thermally stabile, were dried using a
VacuumTherm (Thermo Scientific) vacuum oven overnight.
Glassware used was dried in a UN55 oven (Memmert) at 200
°C.
1H and 13C nuclei nuclear magnetic (NMR) analyses were
performed on a Spectrospin 400 MHz spectrometer (Bruker)
equipped with a SampleXpress (from Bruker) autosampler
system, using deuterated solvents for the preparation of the
samples. The obtained spectra were analyzed using Topspin
7.1 software (Bruker). The chemical shifts were reported
relative to trimethylsilane (TMS), used as a standard (0.00
ppm). Signals were identified and described as singlet (s),
doublet (d), triplet (t), quartet (q), or multiplets (m).
Coupling constants were reported in Hertz (Hz). LC−MS
analyses were performed on a Waters Alliance 2695 system
(Waters), with elution in gradient. High-performance liquid
chromatography (HPLC)-grade solvents were used as a mobile
phase, while a Monolithic C18 50 × 4.60 mm2 column
(Phenomenex) was used as a stationary phase. The UV
detection was performed using a Waters 2996 photoarray
detector (Waters). Mass spectra were collected in both ESI+
and ESI− modes by a Waters QZ instrument (Waters)
coupled to the HPLC system.
Synthesis of (S)-1-Cyclopropyl-6-fluoro-7-(4-(4-((7-
methoxy-5-oxo-2,3,5,11a-tetrahydro-1H-benzo[e]-
Figure 5. Growth inhibition of M. tuberculosis strains by compound 3 or ciprofloxacin. Dose-dependent growth inhibition of M. tuberculosis strains
H37Rv (black), M. tuberculosis 1192/015 (red), and M. tuberculosis 08/00483E (blue) by ciprofloxacin (0.094−6.036 μM) (A) and compound 3
(0.048−3.1 μM) (B). Twofold serial dilutions of each antibiotic were evaluated. The antibiotic activity was ascertained by the addition of resazurin,
and the optical density (OD570nm) was measured. The OD570nm measurements were converted to a percentage of the OD570nm measurements for the
control that contained no antibiotic. The values plotted are a percentage of the growth without antibiotic and are the mean values of three
independent experiments ± standard deviation and analyzed using Student’s t test. Vertical lines indicate modified Gompertz-determined MIC
values.
Table 3. MIC Values ± Standard Deviation, As Determined
Using the Modified Gompertz Function for M. tuberculosis
H37Rv, M. tuberculosis 1192/015, and M. tuberculosis 08/
00483E, Which Were Exposed to Ciprofloxacin and
Compound 3
MIC [μM]
strain reference ciprofloxacin compound 3
H37Rv 0.453 ± 0.088 0.413 ± 0.0004
1192/015 0.386 ± 0.078 1.903 ± 0.031
08/00483E 0.415 ± 0.101 2.153 ± 0.136
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pyrrolo[1,2-a][1,4]diazepin-8-yl)oxy)butanoyl)-
piperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carbox-
ylic acid (3). Alloc, THP protected pyrrolobenzodiazepine
core 2 (200 mg, 0.38 mmol, 1 equiv), and ciprofloxacin ethyl
ester 1 (1.1 equiv) were dissolved in dimethylformamide (10
mL). EDCI (2 equiv) and 4-dimethylaminopyridine (1.75
equiv) were added to the solution, which was left under a
magnetic stirrer overnight at room temperature under a
nitrogen atmosphere. The reaction went to completion after 15
hours and was monitored by LC−MS. Ethyl acetate (30 mL)
was added to the solution, and the organic phase was washed
with a NaHCO3 aqueous saturated solution (2 × 10 mL), citric
acid aqueous saturated solution (2 × 10 mL), and brine (2 ×
10 mL). The organic phase was collected, dried over MgSO4,
and evaporated under vacuum to give the crude of reaction,
which was purified by column chromatography on silica gel
(mobile phase: 95/5, DCM/MeOH, v/v), obtaining 150 mg of
the protected PBD−ciprofloxacin ethyl ester conjugate (3a).
The obtained product 3a was fully characterized using NMR
and MS spectroscopy (ESI). The protected compound 3a was
dissolved in a 1:1 mixture of dioxane/MeOH (6 mL) and
underwent basic hydrolysis, being treated with an aqueous
solution of NaOH 0.1 M (excess). The reaction went to
completion. The reaction mixture was evaporated under
vacuum, H20 (20 mL) was added to the crude, and
subsequently acidified until pH 2, treating with HCl of a 0.1
M aqueous solution. The aqueous phase was extracted with
ethyl acetate (3 × 10 mL) that was subsequently collected,
dried over MgSO4, and evaporated under vacuum to give the
corresponding protected PBD−ciprofloxacin derivative (120
mg). The obtained compound (120 mg) was dissolved in
DCM (3 mL) and treated with tetrakisPd(0) triphenylphos-
phine (0.05 equiv) and pyrrolidine (1.2 equiv). The reaction
went to completion in 20 minutes, and the crude of reaction
was evaporated under vacuum and purified by column
chromatography on silica gel (mobile phase: DCM/MeOH,
93/7, v/v) to give the final PBD−ciprofloxacin compound 3
(PBD−CIP) as a white solid (62 mg, yield calculated on three
steps: 37%).
1H NMR (400 MHz, CHLOROFORM-d) δ: 8.78 (s, 1H),
8.05 (d, J = 12.84 Hz, 1H), 7.66 (d, J = 4.28 Hz, 1H), 7.52 (s,
1H), 7.34 (d, J = 7.05 Hz, 1H), 6.84 (s, 1H), 4.12−4.22 (m,
2H), 3.94 (s, 3H), 3.68−3.85 (m, 6H), 3.50−3.62 (m, 2H),
3.31 (br. s., 5H), 2.58−2.68 (m, 2H), 2.28−2.35 (m, 2H),
2.22−2.28 (m, 2H), 2.03−2.10 (m, 2H), 1.39 (q, J = 5.96 Hz,
2H), 1.10−1.24 (m, 3H).
Molecular Docking of the Compounds to Wild and
Mutant Gyrase A. M. tuberculosis gyrase A structure was
obtained by homology modeling using the Swiss Model
webserver. The sequence identity (SID) and similarity (SIM)
of the target with the template crystal structure of S. aureus
gyrase A (PDB ID code 2XCS) were 55.83% and 0.45,
respectively. The structure was amended using Accelrys
discovery studio and minimized using the AMBER 16.0
package program. AutoDock SMINA was used for blind
molecular docking of ciprofloxacin and compound 3 to the
homology modeled minimized structure of gyrase A from M.
tuberculosis to determine the best binding pocket. Blind
molecular docking was followed by GOLD to perform flexible
molecular docking and determining more precise and
evaluated energies and scores by docking the compounds
into the SMINA identified binding pocket. The GOLD
program calculates a fitness score, which takes into account
the ligand binding position and the ability of the ligand to
stabilize the complex. The fitness score, ChemScore, was used
to determine the best-docked pose for each compound. For
molecule docking of the mutant form of gyrase A, Ser84 was
altered to Leu using PyMOL software, and the new structure of
gyraseA_S84L was minimized using Sybyl program. GOLD
molecular docking was performed on the minimized structure
of the mutant enzyme, and the ligand conformational flexibility
along with the partial flexibility of the protein was thoroughly
examined by a genetic algorithm (GA). The default parameters
were selected (100 population sizes, 5 for the number of
islands, 100 000 number of operations, and 2 for the niche
size) for each run, and the maximum number of runs was set to
20 for each compound. The cutoff values of 4.0 Å for van der
Waals distance and 2.5 Å (dH−X) for hydrogen bonds were
employed.
Microbiological Evaluation. Bacterial Strains and
Reagents. Mycobacterium tuberculosis strains, H37Rv, 1192/
015, and 08/00483E (multidrug-resistant (MDR)), were used
in the modified resazurin microtiter assay (REMA) plate
method. M. tuberculosis Beijing strains 1192/015 and 08/
00483E were obtained from the PHE National Mycobacterial
Reference Laboratory.
Reagents used were Middlebrook 7H9 medium (BD Difco),
OADC supplemented with 0.5% glycerol (24388.295, VWR
Chemicals) and 0.2% Tween 80 (P1754, Sigma), CAMR
Mycobacterium medium MOD2 (CMM MOD2),30 cipro-
floxacin (Sigma-Aldrich, cat no. 33434), and 0.02% resazurin
solution (10 mg resazurin sodium salt (R7017, Sigma-Aldrich)
in 50 mL phosphate-buffered saline, pH 7.4 (Severn Biotech)
containing 5% Tween 80).31 All of the antibiotics were
dissolved in dimethyl sulphoxide (DMSO) (Sigma-Aldrich
D2650) to a stock concentration of 10 mg/mL.
Preparation of Bacterial Inocula. Bacterial strains were
grown in 50 mL of OADC-supplemented, Middlebrook 7H9
medium with 0.5% glycerol and 0.2% Tween 80 in vented
Erlenmeyer flasks, shaken at 37 °C for 5 days. Inoculum for the
REMA method was prepared to an OD540nm of 0.5, from
Middlebrook 7H9 cultures by diluting cells in CMM MOD2
medium.
Modified Resazurin Microtiter Assay (REMA) Plate
Method. A modification of the REMA plate method
previously described by Nateche et al. in 2006 was used.32,33
A 10 mg/mL stock solution of each antibiotic was prepared in
DMSO. A twofold serial dilution of each antibiotic stock
solution was performed in CMM MOD2 medium. The two
antibiotics evaluated were ciprofloxacin (0.094−6.036 μM)
and compound 3 (0.048−3.1 μM). Each antibiotic concen-
tration of 100 μL was added to six replicate wells in a 96-well
plate (734-1554, VWR). Three of the wells were “drug-only”,
and another three wells were “test wells” used to assess the
activity of the antibiotic. Bacterial culture (10 μL) was added
to the test wells to give a final OD540nm of 0.05. Three further
wells contained 100 μL of medium and 10 μL of bacteria as
“drug-free” controls to confirm the growth of the bacteria in
the absence of an antibiotic. The drug-only controls allowed
for confirmation that there was an absence of colorimetric
interference from the antibiotics. Bacteria were diluted to an
optical density (OD540nm) of 0.5, and 10 μL of the inoculum
was added to each of the test wells and the drug-free controls.
Medium (10 μL) was added to the drug-only wells. The plates
were incubated for 7 days at 37 °C while shaking at 200 rpm.
Drug activity was assessed by adding 11 μL resazurin to each
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well of the 96-well plate and then incubating the plate at room
temperature for 6 hours. The optical density (OD570nm) was
measured in each well. The OD570nm measurements were
converted to a percentage of the drug-free control; data were
expressed as a percentage of the growth without an antibiotic.
Statistical Analyses. The average OD570nm for each drug
concentration was fitted to a sigmoidal curve using the
modified Gompertz function (y = A + Ce-e(B(x − M))), and
the minimum inhibitory concentration (MIC) was identified
from the point of inflexion of the lower asymptote.27 This was
applied to the mean of the OD570nm of four biological repeats
to produce a graphical representation for each condition. An
unpaired, two-tailed, Student’s t test was used to determine
significance between biological repeats.
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